Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Abstract

Increasing doses of MTX in combination with adalimumab demonstrated a statistically significant trend in improved clinical outcomes that mimicked the adalimumab pharmacokinetic profile. In early RA patients initiating adalimumab combination therapy, efficacy of 10 and 20 mg/week MTX appeared equivalent.